ERBB2 and neoplasm: Currently, results from the first randomized phase III DETECT-trial (NCT01619111) are awaited, which evaluates addition of the HER2-directed tyrosine kinase inhibitor lapatinib to standard of care in patients with a HER2-negative tumor and HER2-positive CTCs at the start of a new line of treatment.